HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Result: Therefore, we chose three corresponding mutations, M184V, F160M, and Q182G, in HIV-1 RT to investigate resistance to 3TC/ETV in HIV-1F115Y/Y116F/Q151M to 3TC and ETV.
Result: We confirmed previous reports that HIVQ151M and HIV3MB were substantially susceptible to ETV and 3TC, but significantly less susceptible to AZT due to Q151M and F116Y mutations, which are components of the well-known multi-drug resistance Q151M-complex.
Result: We found that two RT molecules in the asymmetric unit were in different conformations: one in a closed conformation identical to other RT3MB ternary complexes, whereas the other molecule was in an
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Discussion: A62VRT is observed in two unusual mutational patterns: the Q151M complex and the T69SSS insertion complex.
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
PMID: 32843050
2020
Antimicrobial resistance and infection control
Conclusion: Detected RAMs were M41L, K70Q, V75I, Q151M, M184V and T215F for NRTI; K103N and V108I for NNRTI; and L10F, K20I, M36I, M46I, I47V, I54L, L63H, L76V, V82S and L89I for PI/r.
Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
Result: One patient had a multidrug-resistant reverse transcriptase mutation present (Q151M) which conferred resistance to all available NRTIs.
Table: Q151M
Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors.
PMID: 30648556
2019
Biochemical and biophysical research communications
Abstract: The most active RT mutant, HIV-1 RT7MC, carrying Q151M/G112S/D113A/Y115F/F116Y/F160L/I159L was successfully crystallized, and its three-dimensional structure was determined in complex with DNA:dGTP/entecavir-triphosphate (ETV-TP), a potent anti-HBV guanosine analogue RT inhibitor, at a resolution of 2.43 A and 2.60 A, respectively.
Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana.
Discussion: The K65R and Q151M substitutions are known to occur more commonly in HIV-2 than in HIV-1 infections, and often appear together with M184V in patients that receive NRTI, as shown in an ART-experienced patient in this study.
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2.
Abstract: With one exception, all resistant viruses had canonical nucleoside reverse transcriptase inhibitors (NRTIs)-associated resistance mutations (K65R, N69S, V111I, Y115F, Q151M and M184V).
HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.
PMID: 31885806
2019
Oxidative medicine and cellular longevity
Result: The most frequent mutation of resistance to NRTI worldwide is M184V/I, followed by K65R/N, L74V/I, Y115F, and Q151M, and the most prevalent for FSU_A is M184V, followed by K65R/N.
HIV mutation literature information.
PMID: 
2020
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT